Dare Bioscience
DARE
34 hedge funds and large institutions have $6.4M invested in Dare Bioscience in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
13% more funds holding
Funds holding: 30 → 34 (+4)
1.81% less ownership
Funds ownership: 8.68% → 6.87% (-1.8%)
22% less capital inflows, than outflows
Capital inflows: $1.44M | Capital outflows: $1.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$749K |
| 2 |
BlackRock
New York
|
+$191K |
| 3 |
Morgan Stanley
New York
|
+$90.7K |
| 4 |
State Street
Boston,
Massachusetts
|
+$89.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.14M |
| 2 |
Virtu Financial
New York
|
-$253K |
| 3 |
Squarepoint
New York
|
-$240K |
| 4 |
Two Sigma Advisers
New York
|
-$130K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$35K |
DARE Hedge Fund Activity: Q2 2021 in Review
34 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q2 2021, worth a combined $6.4M — up 4.9% from $6.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new DARE positions and 5 closed out — a net gain of 4 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $749K. The largest seller was Renaissance Technologies, cutting an estimated $1.14M.
- 34 institutional investors held Dare Bioscience (DARE) as of Q2 2021, up from 30 in Q1 2021.
- Funds reported $6.4M of Dare Bioscience stock for Q2 2021, up 4.9% quarter-over-quarter.
- 9 funds opened new Dare Bioscience positions in Q2 2021 and 5 closed out, a net change of +4 holders.
- The largest Dare Bioscience buyer in Q2 2021 was Vanguard Group, an estimated $749K added.
- The largest Dare Bioscience seller in Q2 2021 was Renaissance Technologies, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2021.